An Open-label, Non-randomized Pharmacokinetic and Safety Study of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Severe Renal Impairment.
Phase of Trial: Phase I
Latest Information Update: 07 Aug 2017
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 08 Apr 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 08 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.